Coagulopathy of Dengue and COVID-19 : Clinical Considerations
department or school: Medicine, Faculty of
department or school: Non UBC
department or school: Anesthesiology, Pharmacology and Therapeutics, Department of
data provider: DSpace
identifier citation: Islam, A.; Cockcroft, C.; Elshazly, S.; Ahmed, J.; Joyce, K.; Mahfuz, H.; Islam, T.; Rashid, H.; Laher, I. Coagulopathy of Dengue and COVID-19: Clinical Considerations. Trop. Med. Infect. Dis. 2022, 7, 210.
creator: Islam, Amin
creator: Cockcroft, Christopher
creator: Elshazly, Shereen
creator: Ahmed, Javeed
creator: Joyce, Kevin
creator: Mahfuz, Huque
creator: Islam, Tasbirul
creator: Rashid, Harunor
creator: Laher, Ismail
issued: 2023-07-18T18:18:16Z
issued: 2022-08-25
description: Thrombocytopenia and platelet dysfunction commonly occur in both dengue and COVID-19 and are related to clinical outcomes. Coagulation and fibrinolytic pathways are activated during an acute dengue infection, and endothelial dysfunction is observed in severe dengue. On the other hand, COVID-19 is characterised by a high prevalence of thrombotic complications, where bleeding is rare and occurs only in advanced stages of critical illness; here thrombin is the central mediator that activates endothelial cells, and elicits a pro-inflammatory reaction followed by platelet aggregation. Serological cross-reactivity may occur between COVID-19 and dengue infection. An important management aspect of COVID-19-induced immunothrombosis associated with thrombocytopenia is anticoagulation with or without aspirin. In contrast, the use of aspirin, nonsteroidal anti-inflammatory drugs and anticoagulants is contraindicated in dengue. Mild to moderate dengue infections are treated with supportive therapy and paracetamol for fever. Severe infection such as dengue haemorrhagic fever and dengue shock syndrome often require escalation to higher levels of support in a critical care facility. The role of therapeutic platelet transfusion is equivocal and should not be routinely used in patients with dengue with thrombocytopaenia and mild bleeding. The use of prophylactic platelet transfusion in dengue fever has strained financial and healthcare systems in endemic areas, together with risks of transfusion-transmitted infections in low- and middle-income countries. There is a clear research gap in the management of dengue with significant bleeding.
aggregated CHO: https://circle.library.ubc.ca/rest/handle/2429/85259
note: Citation: Islam, A.; Cockcroft, C.;Elshazly, S.; Ahmed, J.; Joyce, K.;Mahfuz, H.; Islam, T.; Rashid, H.;Laher, I. Coagulopathy of Dengue andCOVID-19: Clinical Considerations.Trop. Med. Infect. Dis. 2022, 7, 210.https://doi.org/10.3390/tropicalmed7090210Academic Editors: Peter A. Leggat,John Frean and Lucille BlumbergReceived: 21 July 2022Accepted: 22 August 2022Published: 25 August 2022Publisher’s Note: MDPI stays neutralwith regard to jurisdictional claims inpublished maps and institutional affil-iations.Copyright: © 2022 by the authors.Licensee MDPI, Basel, Switzerland.This article is an open access articledistributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Tropical Medicine and Infectious DiseaseReviewCoagulopathy of Dengue and COVID-19: Clinical ConsiderationsAmin Islam 1,2,*, Christopher Cockcroft 1, Shereen Elshazly 1,3 , Javeed Ahmed 4, Kevin Joyce 1, Huque Mahfuz 5,Tasbirul Islam 6, Harunor Rashid 7,8 and Ismail Laher 91 Department of Haematology, Mid & South Essex University Hospital NHS Foundation Trust,Prittlewell Chase, Westcliff-on-Sea SS0 0RY, UK2 Department of Haematology, Queen Mary University of London, Mile End Road, London E1 3NS, UK3 Adult Haemato-Oncology Unit, Faculty of Medicine, Ainshams University, Cairo 11566, Egypt4 Department of Microbiology and Virology, Mid & South Essex University Hospital NHS Foundation Trust,Westcliff-on-Sea SS0 0RY, UK5 Department of Haematology and Oncology, Combined Military Hospital, Dhaka 1206, Bangladesh6 Department of Pulmonology and Critical Care Medicine, Indiana School of Medicine, Lafayette, IN 47907, USA7 National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead,Westmead, NSW 2145, Australia8 Sydney Institute for Infectious Diseases, The University of Sydney, Westmead, NSW 2145, Australia9 Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine,The University…
has type: Article
is shown at: 10.14288/1.0434228
language: eng
peer review status: Reviewed
provider: Vancouver : University of British Columbia Library
publisher: Multidisciplinary Digital Publishing Institute
publisher DOI: 10.3390/tropicalmed7090210
rights: CC BY 4.0
rights URI: https://creativecommons.org/licenses/by/4.0/
scholar level: Faculty
scholar level: Researcher
subject: COVID-19
subject: cross-reactivity
subject: dengue
subject: haemorrhage
subject: thrombocytopenia
subject: thrombosis
type: Text
identifier URI: http://hdl.handle.net/2429/85259